Edition:
United States

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

32.91USD
16 Feb 2018
Change (% chg)

$0.25 (+0.77%)
Prev Close
$32.66
Open
$32.50
Day's High
$34.12
Day's Low
$32.50
Volume
132,970
Avg. Vol
66,407
52-wk High
$37.50
52-wk Low
$26.54

Chart for

About

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $1,144.78
Shares Outstanding(Mil.): 34.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Genomic Health - Oncotype DX Genomic Prostate Score™ Test Increases Use Of Active Surveillance

* ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST INCREASES USE OF ACTIVE SURVEILLANCE BY 30 PERCENT IN LOW-RISK PATIENTS, RESULTING IN GREATER ADHERENCE TO GUIDELINE-BASED CARE Source text for Eikon: Further company coverage:

Feb 05 2018

BRIEF-Genomic Health Announces Research Collaboration with Janssen Pharma

* GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT

Dec 06 2017

BRIEF-Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

* GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS

Nov 28 2017

BRIEF-Genomic Health Q3 loss per share $0.06

* Genomic Health announces third quarter 2017 financial results and reports recent business progress

Nov 08 2017

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​

Sep 13 2017

BRIEF-Palmetto GBA issues positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test

* Palmetto GBA issued positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test Source text for Eikon: Further company coverage:

Aug 24 2017

Earnings vs. Estimates